New drug aims to boost brain energy in Parkinson's patients
NCT ID NCT07322887
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a new drug called SUL-238 can improve energy production in brain cells of people with early, untreated Parkinson's disease. Forty-five participants will take either a low or high dose of SUL-238 or a placebo daily for 28 days. Researchers will use a special MRI scan to measure brain energy levels and check for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SUL-238
What this could lead to
If successful, this could point toward a new way to improve brain cell energy in early Parkinson's, potentially slowing disease progression.
What could go wrong
This is a small, early-phase trial with only 45 people over 28 days. It measures brain chemistry changes, not symptoms or long-term outcomes, so success is uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE (PD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CTC Netherlands BV
RECRUITINGGroningen, 9713 GZ, Netherlands
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact